Further, treatment with the specific TβRI kinase inhibitor SB431542 was potentiated by combination with DMA at low, suboptimal doses, to efficiently inhibit the TGF-β signaling in vitro and in vivo in an orthotopic xenograft breast cancer model. Here, TGFB1 is linked to breast cancer.